2 Results for "

cusatuzumab

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "cusatuzumab" in MCE Product Catalog:

1
Cusatuzumab
Cusatuzumab
0 Images
1 Cited Publications
Cat. No.: HY-P99014
CAS No.: 1864871-20-4
Synonyms: ARGX-110

Target:  

Fc Receptor (FcR) NF-κB

Research Areas:  

Inflammation/Immunology Cancer

Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
Cusatuzumab (FUT8-KO)
Cusatuzumab (FUT8-KO)
0 Images
Cat. No.: HY-P99014A

Target:  

Transmembrane Glycoprotein

Research Areas:  

Cancer

Cusatuzumab (FUT8-KO) is an anti-CD70 monoclonal antibody that prepared by knocking out the fucosyltransferase 8 gene (FUT8) to remove fucose and thereby enhance the ADCC activity of the antibody .
Assay Types